Cite
HARVARD Citation
de Vos, S. et al. (2021). Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leukemia & lymphoma. 62 (4), pp. 810-818. [Online].